2023 World Conference on Lung Cancer (Posters)-P1.22. Predominant Solid Patterns in Advanced EGFR Mutated Lung Adenocarcinoma Treated with TKI Is Associated with Worse Outcomes

P1.22. Predominant Solid Patterns in Advanced EGFR Mutated Lung Adenocarcinoma Treated with TKI Is Associated with Worse Outcomes - PDF(Slides)

Back to course

Pdf Summary

A study conducted at the Thoracic Oncology Department of the Instituto Nacional de Cancerología in Mexico analyzed the outcomes of 333 patients with advanced non-small cell lung cancer who were treated with upfront TKI (Tyrosine Kinase Inhibitor) therapy between January 2013 and December 2022. The study focused on the histological subgroups of adenocarcinoma, specifically examining the presence of micropapillary and solid components.<br /><br />The results of the study showed that patients with solid pattern tumors had a significantly lower median progression-free survival (PFS) of 10 months compared to 17 months for those with non-solid pattern tumors. Similarly, patients with solid pattern tumors had a significantly lower median overall survival (OS) of 20.9 months compared to 29.3 months for those with non-solid pattern tumors.<br /><br />In addition, the study found that the presence of the EGFR mutation type known as L858R and the presence of solid pattern tumors were associated with a higher risk of death. These associations remained significant even after adjusting for other factors in the multivariable analysis.<br /><br />The study concludes that high-grade histological patterns, specifically solid pattern tumors, are associated with worse outcomes in patients with advanced EGFR-mutated non-small cell lung cancer treated with TKI therapy.<br /><br />Overall, this study provides valuable insights into the importance of considering the histological subgroups of adenocarcinoma when determining treatment strategies for patients with advanced lung cancer.

Asset Subtitle

Oscar Arrieta

Meta Tag

Speaker Oscar Arrieta

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

study

advanced non-small cell lung cancer

TKI therapy

histological subgroups

adenocarcinoma

solid pattern tumors

progression-free survival

overall survival

EGFR mutation

treatment strategies